Cftr Trikafta denied as non-formulary by CVS Caremark?

Trikafta covered for FDA-labeled mutations + CF center attestation. Symdeko/Orkambi non-preferred when Trikafta-eligible.

CFF 2023 Modulator Recommendations + CFTR2 database for non-F508del responsive variants. April 2023 FDA expansion to age 2-5 (VX20-445-111). Step-therapy through inferior modulator contradicts CFF first-line Trikafta recommendation.

## Why CVS Caremark Denies Trikafta as Non-Formulary

CVS Caremark manages formularies on behalf of many health plans and employer groups, and specialty drugs like this triple-combination CFTR modulator may be placed on a non-preferred tier, require additional authorization, or be excluded from certain plan designs. A non-formulary denial means the drug does not appear on the plan's approved drug list at a covered tier. However, CVS Caremark and the underlying health plan are required to offer a formulary exception process, and patients with specific genotype-driven medical necessity frequently succeed in obtaining coverage through this channel.

## Your Federal Appeal Rights

Under ACA §2719, plans must provide an exceptions and appeals process for formulary denials. Under ERISA §503, employer plans must provide full-and-fair review. You have 180 days from the denial to file an internal appeal. If denied internally, external independent review is available — typically within four months. Expedited review is available for urgent clinical situations.

## The Concrete Appeal Process

1. Request a formulary exception first — this is often faster than a formal grievance. CVS Caremark has a formulary exception request process through the prescriber's office or via the plan's member services. 2. Identify whether any formulary-covered CFTR modulator alternatives exist and whether they are FDA-approved for this patient's specific mutation profile. If no formulary alternative is approved for this genotype, that is the central exception argument. 3. File a formal internal appeal if the exception request is denied, attaching clinical documentation. 4. Escalate to independent external review if the internal appeal fails.

## Documentation to Gather

• Confirmed CFTR genotype report — the most important single document, because genotype specificity is the primary basis for demonstrating that formulary alternatives are not clinically interchangeable
• Prescriber's formulary exception letter explaining why no formulary-covered alternative is appropriate for this patient's genotype, referencing the FDA-approved prescribing information for both the requested drug and any listed alternatives
• FDA prescribing labels for the requested drug and any formulary alternatives, showing approved indications and mutation profiles
• Clinical notes documenting diagnosis, disease status, and treating provider's clinical reasoning
• Prior history with any formulary alternatives tried, with dates and outcomes, if applicable

## Criteria-Mapping Structure

Obtain CVS Caremark's formulary exception criteria. Then map:

| Exception Criterion | Patient Evidence | |---|---| | No formulary alternative clinically appropriate | Genotype report + label comparison showing indication mismatch | | Medical necessity for non-formulary agent | Prescriber letter citing FDA indication and CF Foundation guidelines | | Patient meets FDA-approved indication | Label excerpt + genotype confirmation | | Prior formulary alternative history (if required) | Medication history with dates and outcomes |

The strongest exception arguments combine genotype specificity with a clear explanation that formulary alternatives are not FDA-approved for this mutation profile. When this argument is well-documented, formulary exceptions for this drug class are frequently granted at the administrative level before a formal internal appeal is even required.